RLAY
Relay Therapeutics, Inc. · Healthcare · Market cap $4.0B
Insiders sold $120.5M net in the last 90 days ·5 sellers, 0 buyers· 8 of 12 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 8, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$130.2M
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Latest filing
Oct 8, 2026
Patel Sanjiv
Relay Therapeutics, Inc. (RLAY) has 32 SEC Form 4 filings (50 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Oct 8, 2026.
Inside the rolling window, 5 insiders at Relay Therapeutics, Inc. reported no open-market purchases and 37 open-market sales totaling $130.2M. The most active filer is Chief Financial Officer Catinazzo Thomas with 14 filings. Insiders have net sold $127.9M over the trailing 6 months. The most recent open-market filing is a sale of 48,199 shares by President and CEO Patel Sanjiv, dated Oct 7, 2026, worth $872K.
- Industry:Biotechnology
- CEO:Sanjiv K. Patel
- Employees:202
- HQ:Cambridge, MA, US
- IPO:2020-07-16
| Source | |||||||
|---|---|---|---|---|---|---|---|
| President and CEO | Sale | 48,199 | $872K | Oct 8 | +5.7% | SEC ↗ | |
| Chief Financial Officer | Sale | 17,717 | $329K | Oct 8 | +5.7% | SEC ↗ | |
| President, R&D | Sale | 8,530 | $162K | Sep 9 | -1.3% | SEC ↗ | |
| Chief Financial Officer | Sale | 17,717 | $336K | Sep 9 | -1.3% | SEC ↗ | |
| President and CEO | Sale | 48,199 | $913K | Sep 9 | -1.3% | SEC ↗ | |
SVF Pauling (Cayman) LtdFirst filing | 10% Owner | Sale | 6,000,000 | $116.4M | Aug 28 | -1.9% | SEC ↗ |
| See remarks | Sale | 4,508 | $90K | Aug 28 | -1.9% | SEC ↗ | |
| Chief Financial Officer | Sale | 17,717 | $350K | Aug 18 | -10.7% | SEC ↗ | |
| President and CEO | Sale | 48,199 | $980K | Aug 18 | -10.7% | SEC ↗ | |
| Chief Financial Officer | Sale | 1,459 | $27K | Jul 30 | — | SEC ↗ | |
| See remarks | Sale | 748 | $14K | Jul 30 | — | SEC ↗ | |
| President, R&D | Sale | 2,237 | $42K | Jul 30 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 17,717 | $331K | Jul 8 | — | SEC ↗ | |
| President, R&D | Sale | 8,660 | $162K | Jul 8 | — | SEC ↗ | |
Patel SanjivFirst in 6 months | President and CEO | Sale | 48,199 | $944K | Jul 8 | — | SEC ↗ |
| See remarks | Sale | 50,000 | $955K | Jul 2 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 187,163 | $3.2M | Jun 24 | — | SEC ↗ | |
| President, R&D | Sale | 93,456 | $1.6M | Jun 24 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 17,717 | $228K | May 14 | — | SEC ↗ | |
Bergstrom Donald AFirst in 3 months | President, R&D | Sale | 1,490 | $22K | Apr 30 | — | SEC ↗ |
| Chief Financial Officer | Sale | 972 | $14K | Apr 30 | — | SEC ↗ | |
Rahmer PeterFirst in 3 months | See remarks | Sale | 753 | $11K | Apr 30 | — | SEC ↗ |
| Chief Financial Officer | Sale | 17,717 | $230K | Apr 9 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 1,800 | $27K | Apr 9 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 17,717 | $178K | Mar 11 | — | SEC ↗ |
Earnings: last 7 quarters
Congress trading RLAY 1 all-time
- DRep. Daniel GoldmanSale$1,001 - $15,0002023-07-12
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does RLAY have?
Relay Therapeutics, Inc. (RLAY) has 32 SEC Form 4 filings (50 transaction rows) in the rolling 365-day window, disclosed by 5 distinct insiders. Most recent filing: Oct 8, 2026.
When was the most recent SEC Form 4 filing for RLAY?
The most recent Form 4 filing for RLAY on Tracefour is dated Oct 8, 2026.
Who is the most active insider at RLAY?
The most active SEC Form 4 filer at RLAY in the rolling window is Chief Financial Officer Catinazzo Thomas, with 14 filings.
What is the net insider flow at RLAY over the last 6 months?
Over the trailing 180 days, insiders at RLAY have net sold $127.9M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at RLAY in the current window?
Inside the rolling window, insiders at RLAY bought $0 and sold $130.2M based on SEC Form 4 filings.
Can I get alerts for RLAY insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Relay Therapeutics, Inc. (RLAY). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Relay Therapeutics, Inc. is in the Healthcare sector.